Thromb Haemost 2005; 93(04): 690-693
DOI: 10.1160/TH02-12-0320
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Activation of coagulation and hyperfibrinolysis in patients with aortic arch atheromatosis (Aortic AA) as a risk factor for cerebral ischemia

Hans-Joachim G. Siemens
1   Department of Internal Medicine, University of Luebeck, Luebeck, Germany
,
Wladimir Mirau
1   Department of Internal Medicine, University of Luebeck, Luebeck, Germany
,
Sabine Brueckner
1   Department of Internal Medicine, University of Luebeck, Luebeck, Germany
,
Juergen Jahn
1   Department of Internal Medicine, University of Luebeck, Luebeck, Germany
2   Borromaeus Hospital, Department of Internal Medicine, Cardiology, Leer, Germany
,
Angela Roth-Isigkeit
1   Department of Internal Medicine, University of Luebeck, Luebeck, Germany
,
Sven Gutsche
1   Department of Internal Medicine, University of Luebeck, Luebeck, Germany
,
Rolf Mitusch
3   Hanseklinikum Stralsund, Cardiology, Stralsund, Germany
,
Abdolhamid Sheikhzadeh
1   Department of Internal Medicine, University of Luebeck, Luebeck, Germany
› Author Affiliations
Further Information

Publication History

Received 20 December 2002

Accepted after revision 17 February 2004

Publication Date:
14 December 2017 (online)

Preview

Summary

In patients with cerebral ischemia, a frequent finding is atheromatous plaques in the ascending aorta and the aortic arch. Since we were able to demonstrate that patients with atrial fibrillation have an increased coagulatory activity, we wanted to evaluate a potential systemic activation of the coagulatory system in patients with aortic arch atheromatosis (Aortic AA). In 134 consecutive patients, we determined several parameters of the co-agulatory and fibrinolytic systems as well as several thrombophilia risk factors and compared the results with 134 age- and sex-matched healthy controls. In 90 of the 134 patients, transesophageal echocardiography showed Aortic AA, and in the remaining 44 patients, there were no aortic findings. The Aortic AA group showed higher concentrations of thrombin-antithrombin (TAT) and plasmin-antiplasmin complexes (PAP). Further division into 4 subgroups of different severity (grade I: no plaques; grade II: plaques 2–5 mm, grade III: plaques > 5 mm, grade IV: mobile plaques), revealed increasing concentrations of fibrinogen, D-dimers and tissue-type plasminogen activator. The grade IV-group displayed the highest values in comparison to all other groups. In conclusion, Aortic AA as such is a risk factor for cerebral ischemia. It causes a systemically detectable activation of coagulation which substantially exceeds the values for controls. This observation is in accordance with our findings in patients with atrial fibrillation.